PRTA PROTHENA CORP PUBLIC LTD CO


$ 10.11 $ -0.23 (-2.22 %)    

Tuesday, 14-Oct-2025 15:59:53 EDT
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 10.32
$ 9.75 x 100
$ 10.81 x 595
$ 10.03 - $ 10.32
$ 4.32 - $ 18.88
392,072
na
544.76M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-prothena-corp-raises-price-target-to-20

HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target ...

 prothenas-partner-bristol-myers-squibb-receives-fast-track-designation-from-the-fda-for-bms-986446-for-the-treatment-of-alzheimers-disease

Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S....

 jmp-securities-maintains-market-outperform-on-prothena-corp-lowers-price-target-to-11

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price targ...

 fda-tightens-safety-guidelines-for-biogen-leqembi-alzheimers-therapy

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, a...

 prothena-reports-non-competitive-brain-swelling-rates-in-early-alzheimers-study

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX0...

 piper-sandler-maintains-overweight-on-prothena-corp-lowers-price-target-to-15

Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target fro...

 chardan-capital-maintains-buy-on-prothena-corp-maintains-18-price-target

Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.

 prothena-reports-phase-1-results-for-prx012-in-alzheimers-explores-partnerships-to-advance-prx012-and-tfr-linked-preclinical-program

As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX0...

 rbc-capital-maintains-sector-perform-on-prothena-corp-lowers-price-target-to-10

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target f...

 hc-wainwright--co-reiterates-buy-on-prothena-corp-maintains-14-price-target

HC Wainwright & Co. analyst Andrew S. Fein reiterates Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $14 price tar...

 chardan-capital-maintains-buy-on-prothena-corp-maintains-18-price-target

Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.

 prothena-corp-q2-adj-eps-173-misses-127-estimate-sales-4420m-miss-6180m-estimate

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION